Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Prime Medicine Inc. has 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 2 distinct examiners and 2 distinct art units. This arrangement shows that the company is pursuing multiple patent applications that are being reviewed independently by different administrative groups.
The busiest examiner, VIJAYARAGHAVAN, JAGAMYA NMN, is responsible for 1 busiest examiner pending action. With a total of 2 pending office actions, the workload is split between the 2 distinct examiners. This suggests a diversified prosecution approach across 2 distinct art units within the biotechnology sector. Practitioners must adapt to the specific nuances of 2 distinct examiners while maintaining a consistent strategy for the technology area.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 62.5% | +49.3% |
| MCKNIGHT, CIARA A | 1 | 60.8% | +38.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | MCKNIGHT, CIARA A | 89d overdue |
| 18702703 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 3 | VIJAYARAGHAVAN, JAGAMYA NMN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | MCKNIGHT, CIARA A | 89d overdue |
| 18702703 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 3 | VIJAYARAGHAVAN, JAGAMYA NMN | — |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| 1656 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18702703 | GENOME EDITING COMPOSITIONS AND METHODS FOR TREATMENT OF USHER SYNDROME TYPE 3 | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §103§112 | Non-Final OA | — | Pending | Apr 18, 2024 |
| 18478179 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | MCKNIGHT, CIARA A | 1656 | §103§112 | Final Rejection | 89d overdue | Pending | Sep 29, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial